Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Monoclonal Antibodies for Multiple Myeloma

July 27th 2016

Immunotherapy Rationale in Multiple Myeloma

July 27th 2016

FDA Grants Daratumumab Combos Breakthrough Designation for Myeloma

July 26th 2016

The FDA granted daratumumab (Darzalex) a breakthrough therapy designation for use in combination with lenalidomide/dexamethasone or bortezomib/dexamethasone as a treatment for patients with multiple myeloma following at least 1 prior therapy.

Dr. Jakubowiak on Finding a Cure for Patients With Multiple Myeloma

July 19th 2016

Andrzej Jakubowiak, MD, PhD, professor of Medicine, director, Myeloma Program, University of Chicago Medicine, discusses the likelihood of finding a cure for patients with multiple myeloma.

Dr. Mateos on Ixazomib-Lenalidomide-Dexamethasone in Multiple Myeloma

July 12th 2016

Daratumumab Triplet Hailed as New Standard for Advanced Myeloma

July 11th 2016

Antonio Palumbo, MD, discusses the practice-changing findings of the phase III CASTOR trial for relapsed/refractory patients and what questions remain with the 3-drug regimen.

Expert: Don't Abandon Use of ASCT for Myeloma in 'Novel-Agent Era'

July 11th 2016

Michele Cavo, MD, provides insight on the results of the randomized phase III European Myeloma Network EMN02/HO95 MM trial for multiple myeloma.

Dr. Pieter Sonneveld on a Prognostic Indicator for Multiple Myeloma

July 5th 2016

EC Grants Expanded Approval for Carfilzomib in Myeloma

July 4th 2016

The European Commission has approved carfilzomib in combination with dexamethasone for adult patients with multiple myeloma who have received at least one prior therapy.

Dr. Shaji Kumar on Novel Frontline Treatment Options in Multiple Myeloma

June 30th 2016

Dr. Mateos on Ixazomib-Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma

June 30th 2016

Final Thoughts on Modern Treatment of Myeloma

June 27th 2016

Emerging Therapies for Myeloma

June 27th 2016

MRD Monitoring in Multiple Myeloma

June 27th 2016

Practical Information on Immunotherapy Use

June 27th 2016

Daratumumab Revolutionizing How Myeloma Is Treated

June 27th 2016

Sequencing Therapies for Multiple Myeloma

June 27th 2016

Pomalidomide In Lenalidomide-Refractory Multiple Myeloma Patients

June 27th 2016

Therapy Based on Rapid versus Slow Progression of Myeloma

June 27th 2016

Upfront Therapy for Transplant -Ineligible Patients

June 27th 2016